Open AccessFemale sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy
Author(s) -
Andrea Antinori,
Francesco Baldini,
Enrico Girardi,
Antonella Cingolani,
Mauro Zaccarelli,
Simona Di Giambenedetto,
Annalisa Barracchini,
Patrizio De Longis,
Rita Murri,
Valerio Tozzi,
Adriana Ammassari,
Maria Gabriella Rizzo,
Giuseppe Ippolito,
Andrea De Luca
Publication year - 2001
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200108170-00018
Subject(s) - nevirapine , rash , medicine , regimen , adverse effect , dermatology , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , viral load
To identify factors associated with cutaneous rash, we performed a retrospective multicentre analysis of HIV outpatients starting a highly active antiretroviral therapy regimen containing nevirapine. A total of 62 cutaneous adverse events were observed in 429 patients. Rash hazard was increased in women, by the prophylactic use of glucocorticoids or antihistaminics, and was reduced by escalating the initial dose of nevirapine. Women receiving glucocorticoids had a 3 month cumulative probability of rash of 0.41.